Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hos-pital and Medical Center, Phoenix, Ari-zona.
Pacific Pituitary Disorders Center, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, California.
Neurosurgery. 2018 Aug 1;83(2):277-280. doi: 10.1093/neuros/nyx401.
The minimal clinically important difference (MCID) is defined as the smallest change in health-related quality of life (QOL) that patients consider meaningful. The MCID is essential for determining clinically significant changes, rather than simply statistically significant changes, in QOL scores. The Anterior Skull Base Nasal Inventory-12 (ASK Nasal-12), a site-specific sinonasal QOL instrument, has emerged as a standard instrument for assessing QOL in patients who have undergone endonasal transsphenoidal surgery.
To determine the MCID for the ASK Nasal-12.
Distribution- and anchor-based methods were used to determine the MCID for the ASK Nasal-12 based on raw data from a multicenter prospective QOL study of 218 patients.
Two distribution-based statistical methods, the one-half standard deviation method and the effect-size method, both yielded MCIDs of 0.37 (medium effect). The first anchor-based method, using the 2-wk postoperative overall nasal functioning item as the anchor, yielded an MCID of 0.31. The second anchor-based method, using the 2-wk postoperative Short Form Health Survey 8 bodily pain item as the anchor, yielded an MCID of 0.29.
The largest MCID obtained for the ASK Nasal-12 using 4 statistical methods 2 wk postoperatively was 0.37. This information provides clinicians with an essential context for determining the clinical significance of changes in QOL scores after interventions. Our results will help clinicians better interpret QOL scores and design future studies that are powered to detect meaningful QOL changes.
最小临床重要差异(MCID)被定义为患者认为有意义的健康相关生活质量(QOL)的最小变化。MCID 对于确定 QOL 评分的临床显著变化至关重要,而不仅仅是统计学上的显著变化。前颅底鼻量表-12(ASK Nasal-12),一种特定于鼻窦的鼻腔 QOL 量表,已成为评估接受经鼻蝶窦手术患者 QOL 的标准量表。
确定 ASK Nasal-12 的 MCID。
使用分布和锚定方法,基于 218 例患者的多中心前瞻性 QOL 研究的原始数据,确定 ASK Nasal-12 的 MCID。
两种基于分布的统计方法,即半标准差法和效应量法,均得出 MCID 为 0.37(中等效应)。第一种基于锚定的方法,使用术后 2 周总的鼻腔功能项目作为锚定,得出 MCID 为 0.31。第二种基于锚定的方法,使用术后 2 周的简短健康调查 8 项身体疼痛项目作为锚定,得出 MCID 为 0.29。
使用 4 种统计方法在术后 2 周获得的 ASK Nasal-12 的最大 MCID 为 0.37。这些信息为临床医生提供了一个确定干预后 QOL 评分变化的临床意义的重要背景。我们的结果将帮助临床医生更好地解释 QOL 评分,并设计未来能够检测到有意义的 QOL 变化的研究。